Insights into early recovery from Long COVID-results from the German DigiHero Cohort.

COVID-19 Long COVID Post COVID Condition SARS-CoV-2

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
13 Apr 2024
Historique:
received: 16 01 2024
accepted: 08 04 2024
medline: 13 4 2024
pubmed: 13 4 2024
entrez: 12 4 2024
Statut: epublish

Résumé

65 million people worldwide are estimated to suffer from long-term symptoms after their SARS-CoV-2 infection (Long COVID). However, there is still little information about the early recovery among those who initially developed Long COVID, i.e. had symptoms 4-12 weeks after infection but no symptoms after 12 weeks. We aimed to identify associated factors with this early recovery. We used data from SARS-CoV-2-infected individuals from the DigiHero study. Participants provided information about their SARS-CoV-2 infections and symptoms at the time of infection, 4-12 weeks, and more than 12 weeks post-infection. We performed multivariable logistic regression to identify factors associated with early recovery from Long COVID and principal component analysis (PCA) to identify groups among symptoms. 5098 participants reported symptoms at 4-12 weeks after their SARS-CoV-2 infection, of which 2441 (48%) reported no symptoms after 12 weeks. Men, younger participants, individuals with mild course of acute infection, individuals infected with the Omicron variant, and individuals who did not seek medical care in the 4-12 week period after infection had a higher chance of early recovery. In the PCA, we identified four distinct symptom groups. Our results indicate differential risk of continuing symptoms among individuals who developed Long COVID. The identified risk factors are similar to those for the development of Long COVID, so people with these characteristics are at higher risk not only for developing Long COVID, but also for longer persistence of symptoms. Those who sought medical help were also more likely to have persistent symptoms.

Identifiants

pubmed: 38609482
doi: 10.1038/s41598-024-59122-3
pii: 10.1038/s41598-024-59122-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8569

Informations de copyright

© 2024. The Author(s).

Références

Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133–146. https://doi.org/10.1038/s41579-022-00846-2 (2023).
doi: 10.1038/s41579-022-00846-2 pubmed: 36639608 pmcid: 9839201
Soriano, J. B., Murthy, S., Marshall, J. C., Relan, P. & Diaz, J. V. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 22, e102–e107. https://doi.org/10.1016/S1473-3099(21)00703-9 (2022).
doi: 10.1016/S1473-3099(21)00703-9 pubmed: 34951953
NICE. COVID-19 rapid guideline: managing the long-term effects of COVID-19 2020: NICE.
Groff, D. et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: A systematic review. JAMA Netw. Open. 4, e2128568. https://doi.org/10.1001/jamanetworkopen.2021.28568 (2021).
doi: 10.1001/jamanetworkopen.2021.28568 pubmed: 34643720 pmcid: 8515212
Lopez-Leon, S. et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 11, 16144. https://doi.org/10.1038/s41598-021-95565-8 (2021).
doi: 10.1038/s41598-021-95565-8 pubmed: 34373540 pmcid: 8352980
Michelen, M. et al. Characterising long COVID: a living systematic review. BMJ Glob. Health 6, e005427. https://doi.org/10.1136/bmjgh-2021-005427 (2021).
doi: 10.1136/bmjgh-2021-005427 pubmed: 34580069
Amdal, C. D. et al. Health-related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19; a systematic literature review. Qual. Life Res. 30, 3367–3381. https://doi.org/10.1007/s11136-021-02908-z (2021).
doi: 10.1007/s11136-021-02908-z pubmed: 34146226 pmcid: 8214069
Kim, Y., Bae, S., Chang, H.-H. & Kim, S.-W. Long COVID prevalence and impact on quality of life 2 years after acute COVID-19. Sci. Rep. 13, 11207. https://doi.org/10.1038/s41598-023-36995-4 (2023).
doi: 10.1038/s41598-023-36995-4 pubmed: 37433819 pmcid: 10336045
Huang, L. et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: A longitudinal cohort study. Lancet Resp. Med. 10, 863–876. https://doi.org/10.1016/S2213-2600(22)00126-6 (2022).
doi: 10.1016/S2213-2600(22)00126-6
Fernández-de-las-Peñas, C. et al. Post–COVID-19 symptoms 2 years after SARS-CoV-2 infection among hospitalized vs nonhospitalized patients. JAMA Netw. Open. 5, e2242106. https://doi.org/10.1001/jamanetworkopen.2022.42106 (2022).
doi: 10.1001/jamanetworkopen.2022.42106 pubmed: 36378309 pmcid: 9667330
Zheng, B. et al. Determinants of recovery from post-COVID-19 dyspnoea: Analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls. Lancet Reg Health Eur. 29, 100635. https://doi.org/10.1016/j.lanepe.2023.100635 (2023).
doi: 10.1016/j.lanepe.2023.100635 pubmed: 37261214 pmcid: 10145209
Diexer, S. et al. Association between virus variants, vaccination, previous infections, and post-COVID-19 risk. Int. J. Infect. Dis. 136, 14–21. https://doi.org/10.1016/j.ijid.2023.08.019 (2023).
doi: 10.1016/j.ijid.2023.08.019 pubmed: 37634619
Organisation for Economic Co-operation, Development. Classifying educational programmes: manual for ISCED-97 implementation in OECD countries. 1999:113.
Robert Koch Institut. Wöchentlicher Lagebericht des RKI zur coronavirus-Krankheit-2019 (COVID-19), 31.03.2022. 2022. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Wochenbericht/Wochenbericht_2022-03-31.pdf?__blob=publicationFile . Accessed 10 Jan 2024.
Hendrickson, A. E. & White, P. O. Promax: A quick method for rotation to oblique simple structure. Brit. J. Stat. Psych. 17, 65–70. https://doi.org/10.1111/j.2044-8317.1964.tb00244.x (1964).
doi: 10.1111/j.2044-8317.1964.tb00244.x
R Core Team. R: A Language and Environment for Statistical Computing.
Ballouz, T. et al. Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts. PLOS One 18, e0281429. https://doi.org/10.1371/journal.pone.0281429 (2023).
doi: 10.1371/journal.pone.0281429 pubmed: 36812215 pmcid: 9946205
Canas, L. S. et al. Profiling post-COVID-19 condition across different variants of SARS-CoV-2: A prospective longitudinal study in unvaccinated wild-type, unvaccinated alpha-variant, and vaccinated delta-variant populations. Lancet Digit. Health. 5, e421–e434. https://doi.org/10.1016/S2589-7500(23)00056-0 (2023).
doi: 10.1016/S2589-7500(23)00056-0 pubmed: 37202336 pmcid: 10187990
Goldhaber, N. H. et al. Deep dive into the long haul: Analysis of symptom clusters and risk factors for post-acute sequelae of COVID-19 to inform clinical care. Int. J. Environ. Res. Pub He. 19, 16841. https://doi.org/10.3390/ijerph192416841 (2022).
doi: 10.3390/ijerph192416841
Kenny, G. et al. Identification of distinct long COVID clinical phenotypes through cluster analysis of self-reported symptoms. Open Forum Infect. Dis 9, 60. https://doi.org/10.1093/ofid/ofac060 (2022).
doi: 10.1093/ofid/ofac060
Subramanian, A. et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 28, 1706–1714. https://doi.org/10.1038/s41591-022-01909-w (2022).
doi: 10.1038/s41591-022-01909-w pubmed: 35879616 pmcid: 9388369
Sahanic, S. et al. Phenotyping of acute and persistent coronavirus disease 2019 features in the outpatient setting: Exploratory analysis of an international cross-sectional online survey. Clin. Infect Dis. 75, e418–e431. https://doi.org/10.1093/cid/ciab978 (2022).
doi: 10.1093/cid/ciab978 pubmed: 34849652
Takakura, K., Suka, M., Kajihara, M. & Koido, S. Clinical features, therapeutic outcomes, and recovery period of long COVID. J. Med. Virol. 95, e28316. https://doi.org/10.1002/jmv.28316 (2023).
doi: 10.1002/jmv.28316 pubmed: 36412057
Sudre, C. H. et al. Attributes and predictors of long COVID. Nat. Med. 27, 626–631. https://doi.org/10.1038/s41591-021-01292-y (2021).
doi: 10.1038/s41591-021-01292-y pubmed: 33692530 pmcid: 7611399
Hartung, T. J. et al. Predictors of non-recovery from fatigue and cognitive deficits after COVID-19: A prospective, longitudinal, population-based study. EClinicalMedicine. 69, 102456. https://doi.org/10.1016/j.eclinm.2024.102456 (2024).
doi: 10.1016/j.eclinm.2024.102456 pubmed: 38333368 pmcid: 10847699
Hernández-Aceituno, A., García-Hernández, A. & Larumbe-Zabala, E. COVID-19 long-term sequelae: Omicron versus Alpha and Delta variants. Infect. Dis. Now. 53, 104688. https://doi.org/10.1016/j.idnow.2023.104688 (2023).
doi: 10.1016/j.idnow.2023.104688 pubmed: 36858287 pmcid: 9970656
Antonelli, M., Pujol, J. C., Spector, T. D., Ourselin, S. & Steves, C. J. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 399, 2263–2264. https://doi.org/10.1016/S0140-6736(22)00941-2 (2022).
doi: 10.1016/S0140-6736(22)00941-2 pubmed: 35717982 pmcid: 9212672
Morioka, S. et al. Post COVID-19 condition of the Omicron variant of SARS-CoV-2. J. Infect. Chemother. 28, 1546–1551. https://doi.org/10.1016/j.jiac.2022.08.007 (2022).
doi: 10.1016/j.jiac.2022.08.007 pubmed: 35963600 pmcid: 9365517
Bachmeier, B. E., Hölzle, S., Gasser, M. & van den Akker, M. How do German general practitioners manage long-/post-COVID? A qualitative study in primary care. Viruses. 15, 1016. https://doi.org/10.3390/v15041016 (2023).
doi: 10.3390/v15041016 pubmed: 37112996 pmcid: 10146752
Koczulla, A. R. et al. S1-Leitlinie Long-/Post-COVID. Pneumologie. 76, 855–907. https://doi.org/10.1055/a-1946-3230 (2022).
doi: 10.1055/a-1946-3230 pubmed: 36479679
Brennan, A. et al. Enhancing the management of long COVID in general practice: A scoping review. BJGP Open. 6, 1. https://doi.org/10.3399/BJGPO.2021.0178 (2022).
doi: 10.3399/BJGPO.2021.0178
Schmachtenberg, T. et al. “There is no one who helps you with it”: Experiences of people with long COVID regarding medical care, therapeutic measures, and barriers in the German healthcare system: Results of a qualitative study with four focus groups. BMC Health Serv. Res. 23, 1160. https://doi.org/10.1186/s12913-023-10170-x (2023).
doi: 10.1186/s12913-023-10170-x pubmed: 37884993 pmcid: 10601213
Macpherson, K. et al. Experiences of living with long COVID and of accessing healthcare services: A qualitative systematic review. BMJ Open. 12, e050979. https://doi.org/10.1136/bmjopen-2021-050979 (2022).
doi: 10.1136/bmjopen-2021-050979 pubmed: 35017239

Auteurs

Sophie Diexer (S)

Institute for Medical Epidemiology, Biometrics and Informatics (IMEBI), Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Magdeburger Str. 8, 06112, Halle (Saale), Germany.

Bianca Klee (B)

Institute for Medical Epidemiology, Biometrics and Informatics (IMEBI), Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Magdeburger Str. 8, 06112, Halle (Saale), Germany.

Cornelia Gottschick (C)

Institute for Medical Epidemiology, Biometrics and Informatics (IMEBI), Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Magdeburger Str. 8, 06112, Halle (Saale), Germany.

Anja Broda (A)

Institute for Medical Epidemiology, Biometrics and Informatics (IMEBI), Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Magdeburger Str. 8, 06112, Halle (Saale), Germany.

Oliver Purschke (O)

Institute for Medical Epidemiology, Biometrics and Informatics (IMEBI), Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Magdeburger Str. 8, 06112, Halle (Saale), Germany.

Mascha Binder (M)

Department of Internal Medicine IV, Oncology/Haematology, Martin Luther University Halle-Wittenberg, Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany.
Division of Medical Oncology, University Hospital Basel, Basel, Switzerland, Petersgraben 4, 4031, Basel, Switzerland.

Michael Gekle (M)

Julius-Bernstein-Institute of Physiology, Medical Faculty of the Martin Luther University Halle-Wittenberg, Magdeburger Str. 6, 06110, Halle (Saale), Germany.

Matthias Girndt (M)

Department of Internal Medicine II, Martin Luther University Halle-Wittenberg, Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany.

Jessica I Hoell (JI)

Paediatric Haematology and Oncology, Martin Luther University Halle-Wittenberg, Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany.

Irene Moor (I)

Institute for Medical Sociology, Martin Luther University Halle-Wittenberg, Magdeburger Str. 8, 06112, Halle (Saale), Germany.

Daniel Sedding (D)

Mid-German Heart Centre, Department of Cardiology and Intensive Care Medicine, University Hospital, Martin Luther University Halle-Wittenberg, Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany.

Jonas Rosendahl (J)

Department of Internal Medicine I, Martin Luther University Halle-Wittenberg, Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany.

Rafael Mikolajczyk (R)

Institute for Medical Epidemiology, Biometrics and Informatics (IMEBI), Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Magdeburger Str. 8, 06112, Halle (Saale), Germany. rafael.mikolajczyk@uk-halle.de.

Classifications MeSH